Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASER-TBM: High-Dose Rifampicin and Linezolid for TBM
NCT03927313Phase 2Completed
- Sponsor
- University of Cape Town
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin, linezolid and aspirin in tuberculous meningitis (TBM) (3 arms), sponsored by University of Cape Town. Primary endpoint: Number of participants in each arm who develop treatment related adverse events at 56 days. Started Jun 2019; status: completed.
02
Drugs
rifampicinlinezolidaspirin
03
Conditions
tuberculous meningitis (TBM)
Beyond the preview
Go deeper on NCT03927313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927313.